UNSPSC 51172422: Asafetida/magnesia

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA900. This VA Drug Class (GA900) classifies this compound as belonging to the group GASTRIC MEDICATIONS, OTHER.

UNSPSC 51172422 Asafetida/magnesia is a Commodity code that does not align with the state and local procurement activity appearing in recent solicitations. The recent opportunities tagged under this code—offender drug testing services, therapeutic pharmacy initiatives, and generic pharmaceutical distribution—address pharmaceutical testing, pharmacy benefit management, and drug supply chain logistics rather than asafetida or magnesia products as discrete commodities. The mismatch suggests either miscoding by the issuing jurisdictions or a fundamental disconnect between the code's nominal scope and current procurement demand under it.

The three recent solicitations span Texas and Minnesota state agencies and a multistate cooperative. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services, valued at $600,000 over two years with optional renewals through five years total, requiring SAMHSA or equivalent lab certification and immunoassay screening with LC/MS/MS or GC/MS confirmation. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 as a preliminary market-intelligence solicitation for direct-to-manufacturer pharmaceutical prescription programs serving state employee and retiree plans. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026 and a two-year initial term. No recent opportunities support activity in asafetida or magnesia purchasing.